1.
纳入研究的基本特征
The basic characteristics of included trials
| Trials | Arm | Case | Gender (M/F) |
Histology | Stage （Ⅲb/Ⅳ） |
Treatment |
| M: male; F: female; TP: Paclitaxel (200 mg/m2) combine with Carboplatin (AUC=6); D: Docetaxel (75 mg/m2); P: Pemetrexed (500 mg/m2); GP: Gemcitabine (1, 250 mg/m2) combine with Cisplatin (80 mg/m2); B: Bevacizumab. | ||||||
| Johnson 2004[3] | 99 | 63/36 | adenocarcinoma, large cell carcinoma, squamous cell carcinoma, other |
15/84 | ||
| Control | 32 | 24/8 | 6/26 | TP | ||
| Observation 1 | 32 | 20/12 | 2/30 | TP+B (7.5 mg/kg) | ||
| Observation 2 | 35 | 19/16 | 7/28 | TP+B (15 mg/kg) | ||
| Sandler 2006[4] | 850 | 463/387 | adenocarcinoma, large cell carcinoma, bronchioloalveolar carcinoma, other |
105/647 | ||
| Control | 433 | 253/180 | 55/337 | TP | ||
| Observation | 417 | 210/207 | 50/310 | TP+B (15 mg/kg) | ||
| Herbst 2007[5] | 81 | 48/33 | large cell carcinoma, adenocarcinoma, other |
— | ||
| Control | 41 | 25/16 | — | D or P+Placebo | ||
| Observation | 40 | 23/17 | — | D or P+B (15 mg/kg) | ||
| Reck 2010[6] | 1, 043 | 665/378 | adenocarcinoma, large cell carcinoma, other |
159/802 | ||
| Control | 347 | 223/124 | 55/266 | GP+Placebo | ||
| Observation 1 | 345 | 223/122 | 48/267 | GP+B (7.5 mg/kg) | ||
| Observation 2 | 351 | 219/132 | 56/269 | GP+B (15 mg/kg) | ||
| Soria 2011[7] | 85 | 47/38 | adenocarcinoma, bronchioloalveolar carcinoma, large cell carcinoma, other |
3/82 | ||
| Control | 41 | 24/17 | 1/40 | TP | ||
| Observation | 44 | 23/21 | 2/42 | TP+B (15 mg/kg) | ||
| Niho 2012[8] | 180 | 115/65 | adenocarcinoma, large cellcarcinoma, other |
40/125 | ||
| Control | 59 | 38/21 | 12/42 | TP | ||
| Observation | 121 | 77/44 | 28/83 | TP+B (15 mg/kg) | ||